# A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

> **NCT03830411** · PHASE2 · UNKNOWN · sponsor: **Xin-Hua Xu** · enrollment: 76 (estimated)

## Conditions studied

- Nonsquamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03830411
- **Lead sponsor:** Xin-Hua Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-13
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2021-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03830411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03830411, "A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03830411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*